Levetiracetam for management of seizures in newborn
Phase 3
Recruiting
- Conditions
- neonatal seizure
- Registration Number
- CTRI/2013/04/003585
- Lead Sponsor
- Rainbow Childrens Hospital
- Brief Summary
to study the therapeutic benefit of levetiracetam in neonatal seizures and to compare efficacy with other anticonvulsant medication.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Babies admitted to NICU with seizures and babies having seizures during NICU stay with •Gestational age ≥ 30 wks Birth weight ≥ 1.5 kg Clinical or electrographic seizures Parental consent obtained.
Exclusion Criteria
Babies with renal serum creatinine > 2.0 Birth at < 30 weeks gestation Parents refuse consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the therapeutic benefit of levetiracetum in neonatal seizures and to compare efficacy with other antiseizure medication. 30/06/2013
- Secondary Outcome Measures
Name Time Method use of leviteracetam in various types of neonatal seizures 30/6/2013
Trial Locations
- Locations (1)
Rainbow Children’s Hospital
🇮🇳Hyderabad, ANDHRA PRADESH, India
Rainbow Children’s Hospital🇮🇳Hyderabad, ANDHRA PRADESH, IndiarabindranPrincipal investigator8712307790rabindranindia@yahoo.co.in